14-Dec-2020 - Waters Corporation

Waters Corporation Appoints Pearl S. Huang to Board of Directors

Waters Corporation announced that Dr. Pearl S. Huang, President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering, has been appointed as a Director of Waters Corporation, effective January 1, 2021.

 “We are pleased to welcome Pearl to the Waters Board of Directors,” said Dr. Flemming Ornskov, Chairman of the Board. “Pearl is a distinguished executive with significant scientific expertise in the discovery of biologics, small molecule and nucleic acid-based therapies, as well as a proven track record in drug discovery and the development of clinical trials. We look forward to benefitting from Pearl’s perspectives and believe she will add even greater value to Waters’ distinguished board of scientists and business leaders.”

“Pearl brings a tremendous blend of scientific expertise, global experience and an entrepreneurial spirit that is vital for Waters as we look to grow our product and services footprint in both pharmaceutical and clinical laboratories around the world,” said Dr. Udit Batra, CEO and President, Waters Corporation. “We are very fortunate to have Pearl join us and I look forward to working with her on our journey ahead.”

“Waters holds an essential position as a pioneering innovator whose products and services enable essential innovation in the life, food and materials sciences,” said Dr. Huang. “I’m honored and excited to work with the Board as well as Udit and the leadership team to leverage my experience to help Waters pursue opportunities for growth in the burgeoning pharma and biopharma industries.”

Dr. Huang is President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering. She currently serves on the boards of Cygnal Therapeutics and KSQ Therapeutics. She previously held senior roles within the pharmaceutical industry, including Senior Vice President and Global Head of Therapeutic Modalities at Roche and Vice President and Global Head of Discovery Academic Partnerships at GSK. Dr. Huang co-founded BeiGene in 2010 and served as its Chief Scientific Officer. Before BeiGene, she led teams in oncology discovery at both Merck and GSK. She has received multiple awards and recognitions throughout her career. In 2020, Dr. Huang was named to the PharmaVOICE 100, a list of the most inspiring leaders in the life sciences, and was featured by FiercePharma as one of the Fiercest Women in Life Sciences. She received her undergraduate degree in life sciences from the Massachusetts Institute of Technology and a Ph.D. in molecular biology from Princeton University.

Facts, background information, dossiers
  • Waters
  • appointments
More about Waters
  • News

    Waters Appoints John M. Ballbach to Board of Directors

    Waters Corporation announced the appointment of John M. Ballbach to its Board of Directors, effective October 5, 2021. Mr. Ballbach currently serves on the Board of RPM International, Inc., a leader in specialty coatings, sealants, building materials and related services. Waters also announ ... more

    Waters Collaborates with Dr. Sunghwan Kim of Kyungpook National University to Advance Precision Analysis of Complex Chemical Compounds

    Waters Corporation has formally expanded its long-standing, collaborative relationship with Dr. Sunghwan Kim of Kyungpook National University to further explore the use of Waters’ cutting-edge ion mobility spectrometry (IMS) in the investigation of compounds in complex mixtures. Identifying ... more

    Waters Corporation Names Udit Batra President and Chief Executive Officer

    Waters Corporation announced that Udit Batra, Ph.D. has been named the Company’s President and Chief Executive Officer, effective September 1, 2020. He will also join Waters’ Board of Directors at that time. Dr. Batra succeeds Christopher O’Connell who will remain in his current roles as Pr ... more

  • Products

    A universal platform for liquid chromatography

    Faster, more reproducible, and accurate data integration with challenging molecules ✓ Shorter time from sample to result, without conditioning ✓ Improved compliance from higher quality data ✓ more

  • Videos

    Performance you need, Results you can trust

    Ever-evolving regulations are impacting LC method approaches for product quality control and beyond. Count on the Arc HPLC System for high-efficiency separations and quality data to help meet your regulatory requirements with confidence. Arc HPLC allows you to easily replicate and improve t ... more

    Did you know that metal interactions can put your analytical results at RISK?

    Non-specific adsorption (NSA) of metal sensitive analytes can lead to loss of sensitivity, poor peak shape, poor reproducibility and lengthy passivation procedures.  The occurrence of these NSA losses can be hard to predict and therefore, a good plan to mitigate them leads to less risk and ... more

    Waters GmbH

    more

  • Companies

    Waters GmbH

    Waters Corporation is a global leader in liquid chromatography (UPLC/HPLC), mass spectrometry (MS), rheology and thermal analysis. The business areas range from research & development, the manufacture and sale of analytical instruments, laboratory software products, column and sample prepar ... more

    Waters GmbH

    Waters Corporation creates business advantage for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide. Pioneering a c ... more

    Waters Ges.m.b.H.

    Since 1958 Waters offers complete solutions in High Performance Liquid Chromatography (HPLC). With our products and services we set the standards in HPLC. Waters Corporation is a multinational, publicly traded (NYSE: WAT) company headquartered in Milford, Massachusetts, USA. The company ha ... more